Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.
研究概览
详细说明
The primary objectives of this protocol are to prospectively collect, process, store, and clinically annotate biospecimens and associated data from participants with urothelial carcinoma and related malignancies of the urinary tract in order to support translational research addressing clinically important scientific questions.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Byron Lee, MD
- 电话号码:713-792-3250
- 邮箱:BHLee@mdanderson.org
学习地点
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- UT MD Anderson Cancer Center
-
接触:
- Bryon Lee, MD
- 电话号码:713-792-3250
- 邮箱:BHLee@mdanderson.org
-
首席研究员:
- Byron Lee, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
UT MD Anderson Cancer Center
描述
Eligibility Criteria
Participants must meet all of the following criteria for enrollment:
- Age 18 years or older at the time of consent.
- Known or suspected urothelial carcinoma or other related malignancy of the urinary tract for which biospecimen and associated clinical data collection is relevant to the objectives of this protocol. This may include patients undergoing diagnostic evaluation for a lesion, mass, abnormal cytology, or other clinical finding concerning for malignancy.
- Undergoing evaluation, treatment, surveillance, follow-up care, or clinically indicated procedures at The University of Texas M.D. Anderson Cancer Center, including Houston Area Locations.
- Able to understand and personally provide informed consent.
- Willing to allow prospective collection, banking, storage, and research use of biospecimens and associated clinical information as described in the informed consent document.
Exclusion Criteria
- Age younger than 18 years.
- Unable to understand the study information or unable to personally provide informed consent.
- Declines participation.
- No known or suspected urothelial carcinoma or other related malignancy of the urinary tract, and no clinical circumstance in which enrollment under this protocol is relevant to the study objectives.
- Clinical, operational, or safety circumstances that make enrollment or research collection inappropriate or not feasible in the judgment of the treating clinical team or study investigators. Examples may include urgent clinical priorities, insufficient residual specimen after diagnostic needs are met, inability to safely obtain research specimens during a clinically indicated procedure, or inability to complete consent appropriately.
- Prisoners or other populations requiring additional regulatory protections not specifically approved under this protocol.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Overall Survival
大体时间:Through study completion; an average of 1 year
|
Through study completion; an average of 1 year
|
合作者和调查者
调查人员
- 首席研究员:Byron Lee, MD、UT MD Anderson Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.